Your email has been successfully added to our mailing list.

×
0 -0.00764006791171482 0 -0.00764006791171482 0.00135823429541593 0 0 -0.000848896434635047
Analyst impact report

Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $72.50 price target on the stock.

CRISPR Therapeutics AG - Common Shares (CRSP) 
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/crsp/real-time
Company Research Source: MarketBeat
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CRSP alerts
Opt-in for
CRSP alerts

from News Quantified
Opt-in for
CRSP alerts

from News Quantified